Moderna has received significant attention recently due to the development of a
combined flu and COVID vaccine, leveraging their innovative
mRNA technology. This development received
approval recommendation from European regulators and was celebrated by the Moderna CEO as being a rigorous scientific review. The vaccine has shown positive results in trials, weighing on its approval prospects. Despite the exuberant response from Europe, the
FDA initially refused to review the vaccine, causing significant waves in the bio-tech market. However, following some back and forth, the US agency reversed its decision and agreed to consider the mRNA flu shot.
Stemming from mRNA technology's success in the pandemic, it's now being employed to combat other diseases, with their efficacy against cancer being in focus. Despite this, there's been a notable challenge with Bayer's Monsanto alleging
mRNA patent infringement against COVID vaccine makers. Additionally, Moderna has been privy to fluctuations in stock value and lingering valuation concerns.
Moderna MRNA News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 28 Feb 2026 07:10:00 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 3
